Non-interventional post-authorization cohort safety study evaluating the effectiveness of the additional risk minimization measures for filgotinib (Jyseleca®) use in patients with moderate to severe active rheumatoid arthritis within European registries

ENCePP Code of conduct

No

Data sources

• Data source(s):
  British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

  Rheumatoid Arthritis - Observation of Biologic Therapies
• Data source(s), other:
  ARTIS Sweden, BIOBADASER Spain, DANBIO Denmark
• Data sources (types):
  Disease registry

  Other
• Data sources (types), other:
  Exposure registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No